Cargando…
In Vitro Effects of Aminopyridyl Ligands Complexed to Copper(II) on the Physiology and Interaction Process of Trypanosoma cruzi
Chagas disease is derived from the infection by the protozoan Trypanosoma cruzi. In many countries, benznidazole is the only drug approved for clinical use despite several side effects and the emergence of resistant parasite strains. In this context, our group has previously pointed out that two nov...
Autores principales: | Silva-Oliveira, Rafaela, Sangenito, Leandro S., Reddy, Andrew, Velasco-Torrijos, Trinidad, Santos, André L. S., Branquinha, Marta H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221635/ https://www.ncbi.nlm.nih.gov/pubmed/37235336 http://dx.doi.org/10.3390/tropicalmed8050288 |
Ejemplares similares
-
Decoding the Anti-Trypanosoma cruzi Action of HIV Peptidase Inhibitors Using Epimastigotes as a Model
por: Sangenito, Leandro S., et al.
Publicado: (2014) -
Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors
por: Sangenito, Leandro Stefano, et al.
Publicado: (2022) -
Lopinavir and Nelfinavir Induce the Accumulation of Crystalloid Lipid Inclusions within the Reservosomes of Trypanosoma cruzi and Inhibit Both Aspartyl-Type Peptidase and Cruzipain Activities Detected in These Crucial Organelles
por: Sangenito, Leandro S., et al.
Publicado: (2021) -
4-Aminopyridyl-Based
CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic
Profile and in Vivo Potency
por: Calvet, Claudia M., et al.
Publicado: (2014) -
Docking simulation between HIV peptidase inhibitors and Trypanosoma cruzi aspartyl peptidase
por: Castilho, Vanessa V. S., et al.
Publicado: (2018)